{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:35:41Z","timestamp":1792236941593,"version":"4.4.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1016\/j.cbi.2004.09.001","type":"journal-article","created":{"date-parts":[[2004,11,8]],"date-time":"2004-11-08T13:44:05Z","timestamp":1099921445000},"page":"53-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Animal models of idiosyncratic drug reactions"],"prefix":"10.1016","volume":"150","author":[{"given":"Jacintha M.","family":"Shenton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack P.","family":"Uetrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2004.09.001_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.all.0000011031.16814.e0","article-title":"Epidemiology of drug allergy","volume":"1","author":"Demoly","year":"2001","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.cbi.2004.09.001_bib2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","article-title":"Timing of new black box warnings and withdrawals for prescription medications","volume":"287","author":"Lasser","year":"2002","journal-title":"J.Am. Med. Assoc."},{"key":"10.1016\/j.cbi.2004.09.001_bib3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0006-2952(87)90707-6","article-title":"Drug-protein conjugates\u2014XI. Disposition and immunogenicity of dinitrofluorobenzene, a model compound for the investigation of drugs as haptens","volume":"36","author":"Park","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1084\/jem.61.5.643","article-title":"Studies on the sensitization of animals with simple chemical compounds","volume":"61","author":"Landsteiner","year":"1935","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cbi.2004.09.001_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0031-6997(25)06749-3","article-title":"Allergic reactions in man","volume":"34","author":"Parker","year":"1982","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.cbi.2004.09.001_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/tx034170b","article-title":"Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development","volume":"17","author":"Evans","year":"2004","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2004.09.001_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/tx980249i","article-title":"New concepts in immunology relevant to idiosyncratic drug reactions: the \u201cdanger hypothesis\u201d and innate immune system","volume":"12","author":"Uetrecht","year":"1999","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2004.09.001_bib8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cbi.2004.09.001_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00130832-200208000-00003","article-title":"Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept","volume":"2","author":"Pichler","year":"2002","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.cbi.2004.09.001_bib10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens\u2013Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.cbi.2004.09.001_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-199716010-00001","article-title":"Role of viral infections in the induction of adverse drug reactions","volume":"16","author":"Levy","year":"1997","journal-title":"Drug Saf."},{"key":"10.1016\/j.cbi.2004.09.001_bib12","first-page":"10","article-title":"Idiosyncratic cutaneous adverse drug reactions in the cat: literature review and report of 14 cases","volume":"26","author":"Scott","year":"1998","journal-title":"Feline Pract."},{"key":"10.1016\/j.cbi.2004.09.001_bib13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1939-1676.2003.tb02495.x","article-title":"Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides","volume":"17","author":"Trepanier","year":"2003","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.cbi.2004.09.001_bib14","series-title":"Fundamental Immunology","first-page":"1069","article-title":"Systemic autoimmunity","author":"Cohen","year":"1999"},{"key":"10.1016\/j.cbi.2004.09.001_bib15","series-title":"Biological Aspects of Disease: Contributions from Animal Models","first-page":"1","article-title":"Animal models of disease: utililty and limitations","author":"Scarpelli","year":"1997"},{"key":"10.1016\/j.cbi.2004.09.001_bib16","first-page":"28","article-title":"Animal models of human disease in drug safety assessment","author":"Boelsterli","year":"2003","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.cbi.2004.09.001_bib17","first-page":"99","article-title":"Halothane-related hepatitis. A clinical study of twenty-six cases","volume":"44","author":"Moult","year":"1975","journal-title":"Q. J. Med."},{"key":"10.1016\/j.cbi.2004.09.001_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00000542-197910000-00008","article-title":"An animal model of halothane hepatotoxicity: roles of enzyme induction and hypoxia","volume":"51","author":"McLain","year":"1979","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cbi.2004.09.001_bib19","first-page":"196","article-title":"Contrasting effects on halothane hepatotoxicity in the phenobarbital-hypoxia and triiodothyronine model: mechanistic implications","volume":"59","author":"Uetrecht","year":"1983","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cbi.2004.09.001_bib20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1056\/NEJM198007103030202","article-title":"Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis","volume":"303","author":"Vergani","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cbi.2004.09.001_bib21","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/bmj.1.6019.1171","article-title":"Unexplained hepatitis following halothane","volume":"1","author":"Walton","year":"1976","journal-title":"Br. Med. J."},{"key":"10.1016\/j.cbi.2004.09.001_bib22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00000542-197205000-00010","article-title":"Hepatic necrosis produced by repeated administration of halothane to guinea pigs","volume":"36","author":"Hughes","year":"1972","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cbi.2004.09.001_bib23","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0022-3565(25)20918-1","article-title":"Guinea-pig model of halothane-associated hepatotoxicity in the absence of enzyme induction and hypoxia","volume":"232","author":"Lunam","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2004.09.001_bib24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00000542-199408000-00027","article-title":"A model for fatal halothane hepatitis in the guinea pig","volume":"81","author":"Lind","year":"1994","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cbi.2004.09.001_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/03602539709037575","article-title":"Characterization of the humoral immune response and hepatotoxicity after multiple halothane exposures in guinea pigs","volume":"29","author":"Chen","year":"1997","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.cbi.2004.09.001_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1006\/taap.1996.8093","article-title":"Demonstration of a cellular immune response in halothane-exposed guinea pigs","volume":"143","author":"Furst","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0300-483X(00)00437-6","article-title":"Role of macrophages and inflammatory mediators in chemically-induced toxicity","volume":"160","author":"Laskin","year":"2001","journal-title":"Toxicology"},{"key":"10.1016\/j.cbi.2004.09.001_bib28","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/hep.1840210424","article-title":"Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen","volume":"21","author":"Laskin","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.cbi.2004.09.001_bib29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/hep.510300104","article-title":"Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species","volume":"30","author":"Michael","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cbi.2004.09.001_bib30","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1021\/tx0255976","article-title":"Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice","volume":"15","author":"Ju","year":"2002","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2004.09.001_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0006-291X(03)00572-2","article-title":"Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease","volume":"304","author":"Masubuchi","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cbi.2004.09.001_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/jhep.2002.30956","article-title":"Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase","volume":"35","author":"Bourdi","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cbi.2004.09.001_bib33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0041-008X(03)00273-4","article-title":"Exaggerated hepatotoxicity of acetaminophen in mice lacking tumor necrosis factor receptor-1. Potential role of inflammatory mediators","volume":"192","author":"Gardner","year":"2003","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib34","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/tx0155505","article-title":"A protective role for cyclooxygenase-2 in drug-induced liver injury in mice","volume":"14","author":"Reilly","year":"2001","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2004.09.001_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0006-291X(02)00466-7","article-title":"Macrophage migration inhibitory factor in drug-induced liver injury: a role in susceptibility and stress responsiveness","volume":"294","author":"Bourdi","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cbi.2004.09.001_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/taap.2002.9474","article-title":"Reduced hepatotoxicity of acetaminophen in mice lacking inducible nitric oxide synthase: potential role of tumor necrosis factor-alpha and interleukin-10","volume":"184","author":"Gardner","year":"2002","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1006\/taap.1997.8301","article-title":"Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents?","volume":"147","author":"Roth","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.103.054288","article-title":"Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats","volume":"307","author":"Luyendyk","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2004.09.001_bib39","series-title":"Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver","author":"Zimmerman","year":"1999"},{"key":"10.1016\/j.cbi.2004.09.001_bib40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00130832-200308000-00001","article-title":"The danger hypothesis applied to idiosyncratic drug reactions","volume":"3","author":"Seguin","year":"2003","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.cbi.2004.09.001_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0300-483X(03)00160-4","article-title":"Modulation of d-penicillamine-induced autoimmunity in the Brown Norway rat using pharmacological agents that interfere with arachidonic acid metabolism or synthesis of inducible nitric oxide synthase","volume":"190","author":"Seguin","year":"2003","journal-title":"Toxicology"},{"key":"10.1016\/j.cbi.2004.09.001_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0300-483X(96)03476-2","article-title":"Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat","volume":"114","author":"Waldhauser","year":"1996","journal-title":"Toxicology"},{"key":"10.1016\/j.cbi.2004.09.001_bib43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01857095","article-title":"Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases","volume":"4","author":"Jaffe","year":"1981","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.cbi.2004.09.001_bib44","series-title":"Autoimmunity and Toxicology: Immune Disregulation Induced by Drugs and Chemicals","first-page":"167","article-title":"Autoimmune reactions to d-penicillamine","author":"Emery","year":"1989"},{"key":"10.1016\/j.cbi.2004.09.001_bib45","first-page":"10","article-title":"Nephropathy induced by d-penicillamine","author":"Lange","year":"1978","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.cbi.2004.09.001_bib46","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4049\/jimmunol.144.8.2985","article-title":"d-Penicillamine-induced autoimmunity in Brown-Norway rats. Similarities with HgCl2-induced autoimmunity","volume":"144","author":"Tournade","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.cbi.2004.09.001_bib47","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ndt\/6.9.621","article-title":"Experimental gold-induced autoimmunity","volume":"6","author":"Tournade","year":"1991","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cbi.2004.09.001_bib48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0041-008X(86)90046-3","article-title":"Mercuric chloride-, gold sodium thiomalate-, and d-penicillamine-induced antinuclear antibodies in mice","volume":"86","author":"Robinson","year":"1986","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0014-4886(82)90100-5","article-title":"d-Penicillamine-induced neuromuscular disease in guinea pigs","volume":"76","author":"McVicker","year":"1982","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.cbi.2004.09.001_bib50","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0090-1229(84)90015-1","article-title":"Effects of prolonged administration of d-penicillamine or captopril in various strains of rats. Brown Norway rats treated with d-penicillamine develop autoantibodies, circulating immune complexes, and disseminated intravascular coagulation","volume":"30","author":"Donker","year":"1984","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.cbi.2004.09.001_bib51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/15563658809000343","article-title":"Autoimmunity induced by chemicals","volume":"26","author":"Bigazzi","year":"1988","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"10.1016\/j.cbi.2004.09.001_bib52","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/art.1780331018","article-title":"d-Penicillamine-induced lupus erythematosus","volume":"33","author":"Enzenauer","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cbi.2004.09.001_bib53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0300-483X(01)00385-7","article-title":"Factors that modify penicillamine-induced autoimmunity in Brown Norway rats: failure of the Th1\/Th2 paradigm","volume":"163","author":"Sayeh","year":"2001","journal-title":"Toxicology"},{"key":"10.1016\/j.cbi.2004.09.001_bib54","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/tx034195a","article-title":"Tolerance induced by low dose d-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated","volume":"17","author":"Masson","year":"2004","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2004.09.001_bib55","first-page":"79","article-title":"Investigation of macrophages and T cells in d-penicillamine-induced autoimmunity in the Brown Norway rat","volume":"1","author":"Masson","year":"2004","journal-title":"J. of Immuntox."},{"key":"10.1016\/j.cbi.2004.09.001_bib56","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature02426","article-title":"Genome sequence of the Brown Norway rat yields insights into mammalian evolution","volume":"428","author":"Gibbs","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.cbi.2004.09.001_bib57","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2460\/javma.1984.184.07.806","article-title":"Propylthiouracil-associated hemolytic anemia, thrombocytopenia, and antinuclear antibodies in cats with hyperthyroidism","volume":"184","author":"Peterson","year":"1984","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.cbi.2004.09.001_bib58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-3565(25)23307-9","article-title":"Propylthiouracil-induced immune-mediated disease in the cat","volume":"234","author":"Aucoin","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2004.09.001_bib59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0300-483X(96)03476-2","article-title":"Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat","volume":"114","author":"Waldhauser","year":"1996","journal-title":"Toxicology"},{"key":"10.1016\/j.cbi.2004.09.001_bib60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/jlb.47.4.321","article-title":"Immunologic consequences of taurine deficiency in cats","volume":"47","author":"Schuller-Levis","year":"1990","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cbi.2004.09.001_bib61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00002018-199512040-00008","article-title":"Drug-induced lupus","volume":"12","author":"Price","year":"1995","journal-title":"Drug Saf."},{"key":"10.1016\/j.cbi.2004.09.001_bib62","series-title":"Autoimmunity and Toxicology: Immune Disregulation Induced by Drugs and Chemicals","first-page":"20","article-title":"Autoimmunity and toxicology: immune disregulation induced by drugs and chemicals","author":"Kammuller","year":"1989"},{"key":"10.1016\/j.cbi.2004.09.001_bib63","series-title":"Dubois\u2019 Lupus Erythematosus","first-page":"156","article-title":"Animal models of systemic lupus erythematosus","author":"Hahn","year":"1987"},{"key":"10.1016\/j.cbi.2004.09.001_bib64","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1172\/JCI119356","article-title":"Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus","volume":"99","author":"Kretz-Rommel","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cbi.2004.09.001_bib65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0090-9556(25)07692-5","article-title":"Metabolism of procainamide to a hydroxylamine by rat and human hepatic microsomes","volume":"12","author":"Uetrecht","year":"1984","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.cbi.2004.09.001_bib66","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.4049\/jimmunol.154.5.2483","article-title":"IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus","volume":"154","author":"Rubin","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.cbi.2004.09.001_bib67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1521-6616(03)00206-7","article-title":"DNA methylation and autoimmune disease","volume":"109","author":"Richardson","year":"2003","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cbi.2004.09.001_bib68","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1073\/pnas.82.9.2560","article-title":"Effect of regional DNA methylation on gene expression","volume":"82","author":"Keshet","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cbi.2004.09.001_bib69","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.4049\/jimmunol.140.7.2197","article-title":"Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity","volume":"140","author":"Cornacchia","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.cbi.2004.09.001_bib70","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1172\/JCI116576","article-title":"Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice","volume":"92","author":"Quddus","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cbi.2004.09.001_bib71","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1172\/JCI118743","article-title":"Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupus-like disease in syngeneic mice","volume":"97","author":"Yung","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cbi.2004.09.001_bib72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0889-857X(21)00573-1","article-title":"Dietary amino acid-induced systemic lupus erythematosus","volume":"17","author":"Montanaro","year":"1991","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.cbi.2004.09.001_bib73","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.7071589","article-title":"Systemic lupus erythematosus-like syndrome in monkeys fed alfalfa sprouts: role of a nonprotein amino acid","volume":"216","author":"Malinow","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.cbi.2004.09.001_bib74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/taap.1995.1179","article-title":"Trichloroethene-induced autoimmune response in female MRL+\/+ mice","volume":"134","author":"Khan","year":"1995","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0300-483X(96)03591-3","article-title":"Autoimmunity caused by xenobiotics","volume":"119","author":"Bigazzi","year":"1997","journal-title":"Toxicology"},{"key":"10.1016\/j.cbi.2004.09.001_bib76","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cbi.2004.09.001_bib77","unstructured":"G.W. Lai, Bioactivation of trimethoprim, fluperlapine and nevirapine: roles of iminoquinone-type michael acceptors in idiosyncratic drug reactions, Pharmaceutical Sciences, University of Toronto, Toronto, 2000."},{"key":"10.1016\/j.cbi.2004.09.001_bib78","first-page":"16","article-title":"Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat","author":"Shenton","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.cbi.2004.09.001_bib79","first-page":"20","article-title":"Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection","author":"Pollard","year":"1998","journal-title":"Clin. Ther."},{"key":"10.1016\/j.cbi.2004.09.001_bib80","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1086\/317536","article-title":"Sex differences in nevirapine rash","volume":"32","author":"Bersoff-Matcha","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cbi.2004.09.001_bib81","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/infdis\/171.3.537","article-title":"High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection","volume":"171","author":"Havlir","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cbi.2004.09.001_bib82","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jama.1934.02750150017005","article-title":"Neutropenia following amidopyrine","volume":"102","author":"Hoffman","year":"1934","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.cbi.2004.09.001_bib83","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000225863","article-title":"Aminoglutethimide-induced leukopenia: a case report and review of the literature","volume":"41","author":"Gez","year":"1984","journal-title":"Oncology"},{"key":"10.1016\/j.cbi.2004.09.001_bib84","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0887-2333(90)90084-7","article-title":"Comparison of in vitro and in vivo hemotoxic effects of aminoglutethimide and glutethimide","volume":"4","author":"Ali","year":"1990","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.cbi.2004.09.001_bib85","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1192\/bjp.169.4.483","article-title":"Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland","volume":"169","author":"Atkin","year":"1996","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.cbi.2004.09.001_bib86","unstructured":"S.L. Iverson, In vitro and in vivo investigations into idiosyncratic drug reactions: the role of reactive metabolites produced by the target tissue in terbinafine-induced cholestatic hepatitis and antipsychotic-induced agranulocytosis, Pharmaceutical Sciences, University of Toronto, Toronto, 2002."},{"key":"10.1016\/j.cbi.2004.09.001_bib87","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0026-895X(24)13268-3","article-title":"A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes","volume":"53","author":"Gardner","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib88","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/taap.1998.8582","article-title":"Atypical antipsychotic-induced neutropenia in dogs","volume":"155","author":"Lorenz","year":"1999","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib89","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0026-895X(24)13269-5","article-title":"A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo","volume":"53","author":"Gardner","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib90","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/bmj.292.6522.721","article-title":"Amodiaquine induced agranulocytosis and liver damage","volume":"292","author":"Neftel","year":"1986","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.cbi.2004.09.001_bib91","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/0006-2952(89)90184-6","article-title":"Drug-protein conjugates\u2014XVIII. Detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat","volume":"38","author":"Christie","year":"1989","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib92","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000235475","article-title":"Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine","volume":"95","author":"Clarke","year":"1991","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.cbi.2004.09.001_bib93","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0006-2952(88)90733-2","article-title":"Drug-protein conjugates\u2014XIV. Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man","volume":"37","author":"Maggs","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2004.09.001_bib94","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000235138","article-title":"Immunogenicity of amodiaquine in the rat","volume":"91","author":"Clarke","year":"1990","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.cbi.2004.09.001_bib95","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0009-2797(02)00057-1","article-title":"Mechanisms of idiosyncratic drug reactions: the case of felbamate","volume":"142","author":"Dieckhaus","year":"2002","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2004.09.001_bib96","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0090-9556(24)15352-4","article-title":"A mechanistic approach to understanding species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions","volume":"28","author":"Dieckhaus","year":"2000","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.cbi.2004.09.001_bib97","first-page":"9","article-title":"Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis","volume":"15","author":"Cribb","year":"1996","journal-title":"Adverse Drug React. Toxicol. Rev."},{"key":"10.1016\/j.cbi.2004.09.001_bib98","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/clinids\/4.2.426","article-title":"Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients","volume":"4","author":"Jick","year":"1982","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.cbi.2004.09.001_bib99","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-100-5-663","article-title":"Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies","volume":"100","author":"Kovacs","year":"1984","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cbi.2004.09.001_bib100","first-page":"783","article-title":"Drug-inducedImmune hypersensitivity disorders in two dogs treated with trimethoprim sulfadiazine: case reports and drug challenge studies","volume":"19","author":"Werner","year":"1983","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"10.1016\/j.cbi.2004.09.001_bib101","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2460\/javma.1985.186.05.479","article-title":"Sulfadiazine-induced allergy in six Doberman pinschers","volume":"186","author":"Giger","year":"1985","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.cbi.2004.09.001_bib102","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2460\/javma.1989.195.11.1612","article-title":"Topics in drug therapy: idiosyncratic reactions to sulfonamides in dogs","volume":"195","author":"Cribb","year":"1989","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.cbi.2004.09.001_bib103","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.4049\/jimmunol.158.10.5002","article-title":"Anti-IL-4 monoclonal antibody prevents antibiotics-induced active fatal anaphylaxis","volume":"158","author":"Park","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.cbi.2004.09.001_bib104","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.pharmtox.37.1.119","article-title":"Transgenic animals as new approaches in pharmacological studies","volume":"37","author":"Wei","year":"1997","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cbi.2004.09.001_bib105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0300-483X(00)00411-X","article-title":"Use of transgenic animals to investigate drug hypersensitivity","volume":"158","author":"Moser","year":"2001","journal-title":"Toxicology"},{"key":"10.1016\/j.cbi.2004.09.001_bib106","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nbt830","article-title":"Production of knockout rats using ENU mutagenesis and a yeast-based screening assay","volume":"21","author":"Zan","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cbi.2004.09.001_bib107","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1126\/science.1088313","article-title":"Generation of fertile cloned rats by regulating oocyte activation","volume":"302","author":"Zhou","year":"2003","journal-title":"Science"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279704001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279704001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T13:09:56Z","timestamp":1757855396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279704001097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S0009279704001097"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2004.09.001","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Animal models of idiosyncratic drug reactions","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2004.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}